Literature DB >> 10536429

Molecular epidemiology of Candida albicans isolates from AIDS and cancer patients using a novel standardized CARE-2 DNA fingerprinting technique.

A Lischewski1, D Harmsen, K Wilms, G Baier, U Gunzer, H Klinker, M Wilhelm, A Schwinn, J Hacker.   

Abstract

A total of 277 Candida isolates from various body sites of 149 AIDS and cancer patients treated in four different university clinics in Würzburg, Germany were collected over a period of 27 months and phenotypically and genotypically characterized. The fingerprinting patterns of 194 Candida albicans isolates obtained with the moderately repetitive, C. albicans-specific DNA fragment CARE-2 were digitized and retrospectively compared with a highly accurate computer-assisted standardization method. A total of 168 different genotypic patterns (< 100% identity) could be differentiated using this technique. Although comparative analysis of C. albicans subsets revealed a pronounced tendency of C. albicans isolates from HIV patients to form clusters, the mean genetic variability in HIV and cancer patient isolates was virtually identical. Patients with a specific disease condition or in a certain age group were not found to harbour C. albicans isolates displaying a characteristic "signature genotype". Micro-evolutionary changes were detected by CARE-2 fingerprinting in temporal successive isolates of one patient, but nosocomial transmission of identical isolates between unrelated patients was never seen. Genotyping showed that patient isolates can replace one another; occasionally also species switches were observed. Secreted aspartic protease (SAP) production was not correlated with a specific C. albicans banding pattern; isolates obtained from HIV patients and from an internal control group secreted comparable amounts of SAP. Candida dubliniensis isolates in this study showed an elevated level of SAP production. When used under standardized conditions, CARE-2 fingerprinting is an efficient, reproducible and sensitive technique to characterize C. albicans isolates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536429     DOI: 10.1046/j.1439-0507.1999.00474.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  6 in total

1.  Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients.

Authors:  Ali Abdul Lattif; Uma Banerjee; Rajendra Prasad; Ashutosh Biswas; Naveet Wig; Neeraj Sharma; Absarul Haque; Nivedita Gupta; Najma Z Baquer; Gauranga Mukhopadhyay
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 2.  Multilocus sequence typing of pathogenic Candida species.

Authors:  Frank C Odds; Mette D Jacobsen
Journal:  Eukaryot Cell       Date:  2008-05-02

3.  Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals.

Authors:  Kaaren G Vargas; Sophie Joly
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  PCR fingerprinting of Candida albicans associated with chronic hyperplastic candidosis and other oral conditions.

Authors:  K L Bartie; D W Williams; M J Wilson; A J Potts; M A Lewis
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

5.  Candida albicans strain maintenance, replacement, and microvariation demonstrated by multilocus sequence typing.

Authors:  F C Odds; A D Davidson; M D Jacobsen; A Tavanti; J A Whyte; C C Kibbler; D H Ellis; M C J Maiden; D J Shaw; N A R Gow
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

6.  Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area.

Authors:  Michael J McCullough; Jacks J Jorge; Flavio Lejbkowicz; Eli Lefler; Faris Nassar; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2004-07       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.